Lead Plaintiff Deadline: August 24, 2021
Please Upload related files below
Fill in below.
Looking for more?
Athira Pharma, Inc. securities between September 18, 2020 and June 17, 2021 and/or purchased common stock of Athira in or traceable to the Company’s registration statement issued in connection with the Company’s September 2020 initial public offering priced at $17.00 per share.
(1) the research conducted by Defendant Kawas, which formed the foundation for Athira’s product candidates and intellectual property, was tainted by Kawas’ scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
In order to be included in the lawsuit, you must have incurred a loss on shares of Athira Pharma, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Athira Pharma, if applicable.
If you suffered a loss in Athira Pharma during the relevant time frame, or pursuant to Athira Pharma’s IPO if listed above, you have until August 24, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.